S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

NRXP NRX Pharmaceuticals Inc

2.08

-0.50 (-19.38%)

After Hours

Last Updated: 17:40:03

Delayed by 15 minutes

NRx Pharmaceuticals reverses gains after a record weekly performance

To read the full story on Seeking Alpha, click here.

NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more NRX Pharmaceuticals Charts.

NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more NRX Pharmaceuticals Charts.

NRX Pharmaceuticals Inc News

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
Tuesday 30 April 2024 (1 day ago) • PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
Thursday 18 April 2024 (2 weeks ago) • PR Newswire (US)

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
Thursday 18 April 2024 (2 weeks ago) • PR Newswire (US)

NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
Wednesday 17 April 2024 (2 weeks ago) • PR Newswire (US)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
Wednesday 17 April 2024 (2 weeks ago) • PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Monday 15 April 2024 (2 weeks ago) • PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Monday 8 April 2024 (3 weeks ago) • PR Newswire (US)

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Monday 1 April 2024 (1 month ago) • PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
Thursday 28 March 2024 (1 month ago) • PR Newswire (US)

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Thursday 28 March 2024 (1 month ago) • PR Newswire (US)

UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Tuesday 26 March 2024 (1 month ago) • PR Newswire (US)

NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
Monday 25 March 2024 (1 month ago) • PR Newswire (US)

More NRX Pharmaceuticals Inc News Articles

Global Developments (PK)

NaturalShrimp (QB)

Mullen Automotive

FBEC Worldwide (PK)

Tonner One World (PK)

Wanderport (PK)

Fannie Mae (QB)

NioCorp Developments

Branded Legacy (PK)

International Star (PK)

Moon Equity (PK)

Virexit Technologies (PK)

Impact Fusion (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions